Use of genetic polymorphisms that associate with efficacy of...

Details Use of genetic polymorphisms that associate with efficacy of... Use of genetic polymorphisms that associate with efficacy of...

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01)

Patent

CA 2541138

The MHC III region of chromosome 6p21.3 harbors a DNA sequence, most likely within the TNF or LTA gene, which influences response to pimecrolimus for the treatment of atopic dermatitis. Accordingly, genetic polymorphisms in the TNF andLTA genes are useful as biomarkers of the efficacy of pimecrolimus treatment of inflammatory disease. By contrast, response to tacrolimus appears to be influenced by other biological pathways.

La région MHC III du chromosome 6p21.3 comporte une séquence d'ADN, plus vraisemblablement dans le gène <I>TNF</I>ou <I>LTA</I>, qui influe sur la réponse au pimecrolimus pour le traitement de la dermatite atopique. En conséquence, les polymorphismes génétiques dans ces gènes sont utiles comme biomarqueurs de l'efficacité du traitement au pimecrolimus pour les maladies inflammatoires. En revanche, la réponse au tacrolimus semble être influencée par d'autres trajets biologiques.

Affiliated with

Also associated with

Rating

Use of genetic polymorphisms that associate with efficacy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of genetic polymorphisms that associate with efficacy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of genetic polymorphisms that associate with efficacy of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1495144